On May 31, 2016 Kite Pharma, Inc., (Nasdaq:KITE) ("Kite") a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer, reported four presentations relating to its clinical programs will be delivered at the upcoming 2016 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, Kite Pharma, MAY 31, 2016, View Source [SID:1234512909]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our presence at this year’s ASCO (Free ASCO Whitepaper) reinforces our progress toward delivering a breakthrough personalized cell therapy for patients with refractory hematological malignancies who have limited or no treatment options," said Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer of Kite. "These data represent a key milestone in our trajectory to advance personalized T cell immuno-oncology and ultimately address critical unmet medical needs."

Data to be presented include results from Kite’s SCHOLAR-1 study, the first and largest meta-analysis of outcomes in patients with chemorefractory diffuse large B-cell lymphoma (DLBCL), an aggressive non-Hodgkin lymphoma (NHL). Patients with chemorefractory DLBCL have not responded to prior treatment with chemotherapy or have relapsed within a year after autologous stem cell transplantation.

Data from a Phase 1-2a study evaluating anti-CD19 CAR T cell therapy after low-dose chemotherapy in people with advanced lymphoma will be presented in a Late-Breaking Abstract oral session by James N. Kochenderfer, M.D., an investigator in the Experimental Transplantation and Immunology Branch of the National Cancer Institute (NCI) Center for Cancer Research. This study is being conducted as part of a Cooperative Research and Development Agreement (CRADA) between Kite and the NCI.

Kite will also provide an update on patients with chemorefractory aggressive NHL from the Phase 1 portion of the ZUMA-1 study and present a poster on the study design of ZUMA-4, an ongoing Phase 1/2 study of KTE-C19 in children and young adults with previously treated acute lymphoblastic leukemia.

Presentations at the 2016 ASCO (Free ASCO Whitepaper) Annual Meeting:

Oral Presentation

Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma

Date: Monday, June 6, 2016, 4:42-4:54 PM CDT
Location: Hall D2
Abstract Number: LBA3010
Presenter: James Kochenderfer, M.D., Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD

Poster Discussion

Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): results from the international SCHOLAR-1 Study

Date: Monday, June 6, 2016, 1:15-2:45 PM CDT
Location: E354b
Abstract Number: 7516
Presenter: Michael Crump, M.D., FRCPC, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Poster Presentations

Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL)

Date: Monday, June 6, 2016, 8:00-11:30 AM CDT
Location: Poster Board 115, Hall A
Abstract Number: 7559
Presenter: Sattva Swarup Neelapu, M.D., The University of Texas MD Anderson Cancer Center, Houston, TX

ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in pediatric and adolescent subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL)

Date: Monday, June 6, 2016, 8:00-11:30 AM CDT
Location: Poster Board 65a, Hall A
Abstract Number: TPS7075
Presenter: Alan S. Wayne, M.D., Children’s Hospital Los Angeles, Los Angeles, CA